BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nardelli S, Pisani LF, Tontini GE, Vecchi M, Pastorelli L. MMX® technology and its applications in gastrointestinal diseases. Therap Adv Gastroenterol 2017;10:545-52. [PMID: 28804515 DOI: 10.1177/1756283X17709974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tursi A, Marinelli A, Laera F, Penna A. Complicated diverticulitis mimicking colonic carcinoma: combined approach with endoscopy and budesonide. BMJ Case Rep 2019;12:e230608. [PMID: 31801775 DOI: 10.1136/bcr-2019-230608] [Reference Citation Analysis]
2 Salice M, Rizzello F, Calabrese C, Privitera Hrustemovic H, Gionchetti P. Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2019;13:607-13. [DOI: 10.1080/17474124.2019.1621745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Deissler H, Krammer H, Gillessen A. pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review). Biomed Rep 2021;15:96. [PMID: 34631051 DOI: 10.3892/br.2021.1472] [Reference Citation Analysis]
4 Maconi G, Camatta D, Cannatelli R, Ferretti F, Carvalhas Gabrielli A, Ardizzone S. Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. Ther Clin Risk Manag 2021;17:285-92. [PMID: 33854320 DOI: 10.2147/TCRM.S263835] [Reference Citation Analysis]
5 Hoy SM. Rifamycin SV MMX®: A Review in the Treatment of Traveller's Diarrhoea. Clin Drug Investig 2019;39:691-7. [PMID: 31172447 DOI: 10.1007/s40261-019-00808-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]